vs
Apellis Pharmaceuticals, Inc.（APLS）与Hinge Health, Inc.（HNGE）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Hinge Health, Inc.的1.1倍（$199.9M vs $182.3M），Hinge Health, Inc.净利率更高（19.3% vs -29.5%，领先48.8%），Hinge Health, Inc.同比增速更快（47.2% vs -5.9%），Hinge Health, Inc.自由现金流更多（$41.6M vs $-14.3M）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Hinge Health是全球领先的数字肌肉骨骼健康解决方案提供商，面向企业雇主、健康保险机构及个人用户，提供结合临床验证的运动疗法、疼痛管理、一对一健康指导的综合性干预服务，业务覆盖北美、欧洲等地区。
APLS vs HNGE — 直观对比
营收规模更大
APLS
是对方的1.1倍
$182.3M
营收增速更快
HNGE
高出53.2%
-5.9%
净利率更高
HNGE
高出48.8%
-29.5%
自由现金流更多
HNGE
多$55.8M
$-14.3M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $182.3M |
| 净利润 | $-59.0M | $35.1M |
| 毛利率 | — | 84.6% |
| 营业利润率 | -25.6% | 17.6% |
| 净利率 | -29.5% | 19.3% |
| 营收同比 | -5.9% | 47.2% |
| 净利润同比 | -62.2% | 105.0% |
| 每股收益（稀释后） | $-0.40 | $0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHNGE
| Q1 26 | — | $182.3M | ||
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $154.2M | ||
| Q2 25 | $178.5M | $139.1M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | — |
净利润APLSHNGE
| Q1 26 | — | $35.1M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-1.8M | ||
| Q2 25 | $-42.2M | $-575.7M | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | — |
毛利率APLSHNGE
| Q1 26 | — | 84.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 81.8% | ||
| Q2 25 | — | 70.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率APLSHNGE
| Q1 26 | — | 17.6% | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -4.0% | ||
| Q2 25 | -18.6% | -417.5% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — |
净利率APLSHNGE
| Q1 26 | — | 19.3% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -1.2% | ||
| Q2 25 | -23.6% | -413.8% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | — |
每股收益（稀释后）APLSHNGE
| Q1 26 | — | $0.41 | ||
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $-0.02 | ||
| Q2 25 | $-0.33 | $-13.10 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $186.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $111.7M |
| 总资产 | $1.1B | $728.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSHNGE
| Q1 26 | — | $186.7M | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $480.0M | ||
| Q2 25 | $370.0M | $413.3M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSHNGE
| Q1 26 | — | $111.7M | ||
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $208.0M | ||
| Q2 25 | $156.3M | $173.8M | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — |
总资产APLSHNGE
| Q1 26 | — | $728.8M | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $769.8M | ||
| Q2 25 | $821.4M | $693.7M | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $43.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $41.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 22.8% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSHNGE
| Q1 26 | — | $43.1M | ||
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $82.4M | ||
| Q2 25 | $4.4M | $25.1M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | — |
自由现金流APLSHNGE
| Q1 26 | — | $41.6M | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $82.3M | ||
| Q2 25 | $4.4M | $24.9M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSHNGE
| Q1 26 | — | 22.8% | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 53.4% | ||
| Q2 25 | 2.5% | 17.9% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSHNGE
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSHNGE
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HNGE
暂无分部数据
